Global CRO expands its operational footprint into Singapore and Malaysia, strengthens China presence, and grows India operations - creating a powerhouse in the Asia Pacific region
ADELAIDE, Australia, June 19, 2026 (GLOBE NEWSWIRE) -- Avance Clinical, the Australian-headquartered global Contract Research Organization (CRO) for biotechs, today announced a significant expansion of its Asia Pacific and China operations, reinforcing its position as the leading CRO partner for international biotech companies seeking access to the region’s diverse patient populations, scientific infrastructure, and accelerated clinical trial timelines.
The expansion extends Avance Clinical’s established Asian footprint - which includes South Korea and Taiwan - to now encompass Singapore and Malaysia, where the company is actively building dedicated clinical operations teams. Simultaneously, Avance Clinical has expanded into mainland China, with commercial operations based in Shanghai and Beijing to serve the country’s rapidly growing biotech innovation hubs. In India, where Avance Clinical has maintained a business presence and biometrics hub, clinical operations are also being scaled to meet increasing demand.
“This expansion reflects the growing strategic importance of Asia Pacific and China to our biotech clients around the world,” said Mark Harvill, Chief Executive Officer of Avance Clinical. “US and international biotechs are increasingly recognising APAC as a high-value region for clinical development - whether for patient access, trial diversity, or speed to key milestones. With boots on the ground across South Korea, Taiwan, Singapore, Malaysia, India, and now mainland China, we can offer an integrated, seamless delivery model that few CROs can match.”
The moves position Avance Clinical to serve as a single accountable partner for multi-country Asian trials, with the regulatory expertise, site relationships, and operational infrastructure to deliver high-quality data that meets global standards.
Jessica Han, Director, Asian Operations, who leads Avance Clinical’s regional strategy from the company’s Seoul, South Korea office, brings over 18 years of clinical research experience across global and regional CROs. “APAC is a collection of highly sophisticated biotech ecosystems, each with its own regulatory frameworks, patient populations, and clinical infrastructure,” said Han. “Our expansion into Singapore and Malaysia opens access to clinical trial clusters that complement our existing strength in Korea and Taiwan, while our China presence means we can now engage directly with the world’s fastest-growing biotech market. For US biotechs this creates unprecedented flexibility in how they design and execute their global development programs.”
Avance Clinical will highlight its expanded APAC and China capabilities at the 2026 BIO International Convention in San Diego, June 22–25, where the company will be exhibiting at Booth #5352. Senior representatives including members of the Asia Operations leadership team will be available throughout the event to discuss multi-regional trial strategies, patient enrolment in APAC, and how Avance Clinical’s GlobalReady delivery model can accelerate development timelines for companies at every stage from First-in-Human through to late-phase pivotal trials.
Biotechs attending BIO International 2026 are encouraged to book a meeting with the Avance Clinical team in advance at www.avancecro.com/book-a-meeting, indicating ‘BIO 2026’ in the notes field.
About Avance Clinical
Avance Clinical is a full-service, Australian-headquartered global Contract Research Organization, servicing international biotechs across North America, Europe, Asia Pacific and China. Specialising in early-phase and First-in-Human studies across more than 250 indications, as well as Oncology, Renal/Cardiometabolic, and Central Nervous System trials, Avance Clinical has partnered with more than 710 emerging biotech companies to accelerate their programs to critical development milestones. Avance Clinical is the 2026 Frost & Sullivan Global Company of the Year in the Biotech CRO industry. To learn more, visit www.avancecro.com.
Find out more:
- Discover Avance Clinical’s GlobalReady model for multi-phase global clinical trials
- Book a meeting with our team at BIO International 2026 in San Diego
- Request a proposal
Media Contact
media@avancecro.com
-
FP Markets荣膺2026年Global UF Awards“最值得信赖经纪商”塞浦路斯利马索尔2026年6月19日 美通社 -- 全球多资产外汇及差价合约经纪商FP Markets 《https:www.fpmarkets.com》在2026年Global UF Awards中荣获“最值得信赖2026-06-19
-
CHARLES S. COHEN向Fortress Investment GROUP偿还判决债务纽约2026年6月19日 美通社 -- Cohen Brothers Realty Corporation总法律顾问David López报告称,Cohen Brothers Realty Corporation总法律顾问宣布,开发商2026-06-19
-
Avance Clinical Announces Asia Pacific and Mainland China Expansion Ahead of BIO International ConveGlobal CRO expands its operational footprint into Singapore and Malaysia, strengthens China presence, and grows India operations - creating a powerh2026-06-19
-
双轮驱动:产业与研学共绘乡村振兴新图景在内黄县六村镇这片充满活力的土地上,乡村振兴的画卷正徐徐展开。以灵芝菇产业为代表的特色农业与以红耕文化为核心的研学教育,如同两个强劲的引擎,通过产业发展与就2026-06-19
-
Bitget 报告:54% 的 Web3 有志从业者无法获得第一份工作塞舌尔维多利亚, June 19, 2026 (GLOBE NEWSWIRE) -- 全球最大的全景交易所 (UEX) Bitget 发布了其《Web3 下一代人才情报报告》 (Web3 Next-Gen Talent Intell2026-06-19
-
AMD股价暴跌17%创近9年之最,苏姿丰紧急回应:AI增速远超想象
-
Ledger 中国销售渠道说明:广州馨潇贸易有限公司官方直营渠道公示
-
江苏省脑机接口产业联盟在宁成立,麦澜德分享前沿成果
-
艾芬达入选国家知识产权强国建设示范创建对象:二十载长期主义,兑现每一份用户价值
-
Esentia宣布成功完成2033年到期的6.125%优先票据和2038年到期的6.500%优先票据的定价
-
中荷人寿北京分公司成功举办中荷创享家品牌发布暨协同发展启航仪式
-
华为系具身智能公司具脑磐石完成新一轮融资:对标JEPA,押注类脑智能的认知世界模型
-
北京暑假补习班有哪些?家长首推一对一权威机构金博升学
-
上海高新技术企业代理机构深度访谈与推荐
-
2026 雷瓦亮相京东 MALL ,匠心筑造专业造型新标杆

